Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 20, 2019 - The FDA announced the approval of Novo Nordisk’s Rybelsus (semaglutide), as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Return to publications